Zura Bio

About:

Zura Bio is a clinical-stage biotechnology company that develops medicines for immune system disorders.

Website: https://zurabio.com

Top Investors: RA Capital Management, Deep Track Capital, Great Point Partners, Access Biotechnology, Armistice Capital

Description:

Zura Bio offers therapies for patients by incorporating immunology resources into phase 2 development programs, such as ZB-168 and torudokimab, with auto-immune illnesses. ZB-168 is an anti-IL7R inhibitor that may have an effect on disorders whose biological pathways are IL7 and TSLP. They create therapeutic indications for ZB-168 that build on the type 1 diabetes data from Phase 1b studies and show a profile and biological basis. The phase 2 clinical development stage of torudokimab, a human-affinity monoclonal antibody that neutralizes IL33, has been established.